EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM

Hongyan Zhu iD, Jingli Liao, Wei Wu, Fenfen Gu, Tong Zhu, Xiaohui Huang, Jian Zhang iD, Lixia Li iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.00937-26 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Hongyan Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Enterococcus, Gram-Positive Bacterial Infections, Vancomycin. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vancomycin is widely utilized in the treatment of Enterococcus infections; however, the optimal pharmacokinetic/pharmacodynamic (PK/PD) targets, specifically the 24 h area under the concentration-time curve at steady state (AUC 24h ), and trough concentration ( C min ), remain undefined. This study aims to examine the relationship between vancomycin exposure and clinical outcomes in Enterococcus infections while establishing PK/PD target values. A retrospective observational analysis was performed on 154 hospitalized patients diagnosed with Enterococcus infections treated with vancomycin. Clinical efficacy, acute kidney injury (AKI), 30-day all-cause mortality, and 14-day bacterial clearance were evaluated. Multivariate logistic regression, Cox regression, and receiver operating characteristic curve analysis were employed to identify independent predictors and determine optimal exposure thresholds. The clinical efficacy rate was 72.1%, with an AKI incidence of 20.8%, a 30-day all-cause mortality rate of 14.3%, and a 14-day bacterial clearance rate of 77.9%. Multivariate analysis identified C-reactive protein >100 mg/L, the presence of bloodstream infections, and an AUC 24h > 380.00 mg·h/L as independent predictors of clinical efficacy. AUC 24h > 540.00 mg·h/L and the Sequential Organ Failure Assessment (SOFA) score were independently associated with the occurrence of AKI. Independent risk factors for 30-day mortality included the SOFA score, surgery, age >60 years, and AUC 24h > 580.00 mg·h/L. Intra-abdominal infections and C min > 11.00 mg/L were identified as independent predictors of 14-day bacterial clearance. For Enterococcus spp ., the recommended therapeutic target ranges are AUC 24h 370–540 mg·h/L and C min 10–14 mg/L. For Enterococcus faecium , the optimal therapeutic window is AUC 24h 425–560 mg·h/L and C min 10–18 mg/L. Optimized vancomycin exposure targets vary by Enterococcus species. A stratified PK/PD-guided approach—utilizing a broader initial target when the species is unknown and a refined target range for confirmed E. faecium —may enhance therapeutic efficacy while minimizing nephrotoxicity. These findings provide evidence supporting individualized vancomycin dosing in the treatment of enterococcal infections. IMPORTANCE Enterococcus infections pose a significant treatment challenge, as optimal vancomycin dosing remains poorly defined. This study establishes evidence-based, species-specific exposure targets. For Enterococcus spp ., the recommended targets are AUC 24h 370–540 mg·h/L and C min 10–14 mg/L; for Enterococcus faecium , a refined window of AUC 24h 425–560 mg·h/L and C min 10–18 mg/L is proposed. These findings have important implications for individualized dosing and patient outcomes in Enterococcus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsEnterococcusGram-Positive Bacterial InfectionsVancomycinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAcute Kidney InjuryArea Under CurveMicrobial Sensitivity TestsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Enterococcusindividualized therapypharmacokinetics/pharmacodynamics (PK/PD)therapeutic drug monitoring (TDM)vancomycin

Substanzen

Anti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Dalian Medical University, Dalian, China.
  • Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Hongyan Zhu, Jian Zhang, Lixia Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, H., Liao, J., Wu, W., Gu, F., Zhu, T., Huang, X., Zhang, J., & Li, L. (2026). PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00937-26

Vancouver

Zhu H, Liao J, Wu W, Gu F, Zhu T, Huang X, et al. PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00937-26

BibTeX
@article{Zhu2026,
  author = {Zhu, Hongyan and Liao, Jingli and Wu, Wei and Gu, Fenfen and Zhu, Tong and Huang, Xiaohui and Zhang, Jian and Li, Lixia},
  title = {PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.00937-26}
}
Kostenlos starten →